Truist Securities Maintains Buy on Globus Medical, Lowers Price Target to $90
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $100 to $90.
Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $100 to $90.